COLO B Coloplast A/S Class B

Coloplast A/S - Announcement no. 07/2021 – Annual Report 2020/21 & Remuneration Report 2020/21

Coloplast A/S - Announcement no. 07/2021 – Annual Report 2020/21 & Remuneration Report 2020/21

Financial highlights for the year 2020/21

  • Coloplast delivered 7% organic growth for the full year. Reported revenue in DKK was up by 5% to DKK 19,426 million. Organic growth rates by business area: Ostomy Care 6%, Continence Care 5%, Interventional Urology 19%, Wound & Skin Care 8%.
  • EBIT before special items amounted to DKK 6,355 million, a 9% increase from last year, corresponding to an EBIT margin before special items of 33% against 32% last year, reflecting efficiency gains and lower spending due to COVID-19 offset by commercial investments.
  • ROIC after tax before special items was 45% against 46% last year, negatively impacted by the acquisition of Nine Continents Medical. Diluted earnings per share (EPS) before special items increased by 19% to DKK 23.36.
  • The Board of Directors recommends a year-end dividend of DKK 14.00 per share, which brings the total dividend for the year to DKK 19.00 per share, compared to DKK 18.00 per share last year.

Financial guidance for 2021/22

  • Organic revenue growth expected around 7% at constant exchange rates. Reported growth in DKK expected around 8%.
  • Reported EBIT margin is expected to be around 32%, impacted by normalization of business activities, raw material price pressure and wage inflation in Hungary and continued commercial investments.
  • Capital expenditures expected to be around DKK 1.2 billion. The effective tax rate is expected to be 22-23% positively impacted by increased R&D cost deductibility which continues in 21/22.



Please find our Annual Report 2020/21 and Remuneration Report 2020/21 in the links below.





For further information, please contact


  

Investors and analysts

Anders Lonning-Skovgaard

Executive Vice President, CFO

Tel.

Ellen Bjurgert

Vice President, Investor Relations

Tel. /

Email:

Aleksandra Dimovska

Sr. Manager, Investor Relations

Tel. /

Email:                                                                        

Press and the media

Peter Mønster

Sr. Media Relations Manager

Tel.

Email:

Address

Coloplast A/S

Holtedam 1

DK-3050 Humlebaek

Denmark

Company reg. (CVR) no. 69749917

Website

 

This announcement is available in a Danish and an English-language version. In the event of discrepancies, the Danish version shall prevail.

Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate health care. Our business includes Ostomy Care, Continence Care, Wound and Skin Care and Interventional Urology. We operate globally and employ about 12,500 employees.

The Coloplast logo is a registered trademark of Coloplast A/S. © 2021-11.

All rights reserved Coloplast A/S, 3050 Humlebaek, Denmark.

Attachments



EN
01/11/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Coloplast A/S Class B

 PRESS RELEASE

Coloplast A/S - Opdateret finanskalender 2025-26

Coloplast A/S - Opdateret finanskalender 2025-26 Venligst se vedlagte pdf.  Opdatering af datoer i finanskalenderen Coloplast har opdateret datoerne i selskabets finanskalender vedrørende offentliggørelsen af årsregnskabet for 2025/26 samt afholdelsen af den ordinære generalforsamling 2026. De opdaterede datoer er som følger: Årsregnskabsmeddelelse for 2025/26 og Årsrapport 2025/26: ændret fra 5. november 2026 til 3. november 2026Ordinær generalforsamling 2026: ændret fra 3. december 2026 til 1. december 2026 For yderligere information og kalenderinvitationer til kommende beg...

 PRESS RELEASE

Coloplast A/S - Updated Financial Calendar 2025-26

Coloplast A/S - Updated Financial Calendar 2025-26 Please see enclosed pdf. Update to Financial Calendar Dates Coloplast has updated the dates in its financial calendar for the publication of the FY Financial Statements 2025/26 and the Annual General Meeting 2026.  The updated dates are as follows: Financial Statements for the full year 2025/26 and Annual Report 2025/26: changed from November 5, 2026 to November 3, 2026Annual General Meeting 2026: changed from December 3, 2026 to December 1, 2026 For more information and calendar invitations for upcoming events, please visit:   Kind...

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen

ResearchPool Subscriptions

Get the most out of your insights

Get in touch